Recursion (RXRX) news

Tempus, recursion deal has $42M committed payments over 3 years

Tempus AI, - Recursion grants Tempus non-exclusive worldwide license to RNA sequencing model TXFM

Recursion Pharmaceuticals has granted Tempus AI a non-exclusive, worldwide license to its RNA sequencing model, TXFM, as part of an ongoing collaboration between the two companies. This agreement builds on a previously announced data collaboration deal, which aims to leverage advanced AI-driven…

Tempus & recursion extend existing data license pact

Recursion Pharmaceuticals and Tempus have extended their existing data licensing agreement, further solidifying their collaboration in the life sciences data space. The expanded partnership aims to enhance access to high-quality, real-world data to support drug discovery and development efforts.…

Recursion Pharmaceuticals - Eliminates co's right to terminate agreement for convenience - SEC filing

Recursion Pharmaceuticals, Inc. has amended a contractual provision that previously granted a counterparty the right to terminate an agreement for convenience. The change was disclosed in a recent SEC filing . The adjustment removes the termination-for-convenience clause, which may affect the…

Recursion Pharmaceuticals - Extends agreement term from five to six years - SEC filing

Recursion Pharmaceuticals, Inc. has announced an extension of its agreement term from five to six years, as disclosed in a recent SEC filing . The updated agreement, detailed in the company's S-1 registration statement , reflects adjustments to the original contractual terms, potentially aligning…